Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accumulated Expenses: 2014-2024

Historic Accumulated Expenses for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2024 value amounting to $10.0 million.

  • RedHill Biopharma's Accumulated Expenses rose 209.83% to $693,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $693,000, marking a year-over-year increase of 209.83%. This contributed to the annual value of $10.0 million for FY2024, which is 117.62% up from last year.
  • RedHill Biopharma's Accumulated Expenses amounted to $10.0 million in FY2024, which was up 117.62% from $4.6 million recorded in FY2023.
  • RedHill Biopharma's Accumulated Expenses' 5-year high stood at $24.1 million during FY2020, with a 5-year trough of $4.6 million in FY2023.
  • Its 3-year average for Accumulated Expenses is $10.8 million, with a median of $10.0 million in 2024.
  • In the last 5 years, RedHill Biopharma's Accumulated Expenses surged by 456.04% in 2020 and then slumped by 74.42% in 2023.
  • Yearly analysis of 5 years shows RedHill Biopharma's Accumulated Expenses stood at $24.1 million in 2020, then fell by 13.23% to $20.9 million in 2021, then dropped by 14.10% to $17.9 million in 2022, then crashed by 74.42% to $4.6 million in 2023, then soared by 117.62% to $10.0 million in 2024.